Current Report Filing (8-k)
12 11월 2019 - 10:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT Pursuant to Section 13
or 15(d)
of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 12, 2019
AVADEL PHARMACEUTICALS PLC
(Exact
name of registrant as specified in its charter)
Ireland
(State or Other Jurisdiction
of
Incorporation)
|
001-37977
(Commission
File Number)
|
98-1341933
(I.R.S. Employer
Identification No.)
|
Block 10-1
Blanchardstown Corporate Park, Ballycoolin
Dublin 15, Ireland
(Address of Principal Executive Offices)
|
Not Applicable
(Zip Code)
|
Registrant’s
telephone number, including area code: +353 1 485 1200
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section
12(b) of the Act:
Title
of each class
|
|
Ticker
symbol(s)
|
|
Name
of each exchange on which registered
|
American Depositary Shares*
|
|
AVDL
|
|
NASDAQ Stock Market LLC
|
Ordinary Shares**
|
|
|
|
(NASDAQ Global Market)
|
|
*
|
American Depositary Shares may be evidenced by American
Depository Receipts. Each American Depositary Share represents one (1) Ordinary Share.
|
|
**
|
Nominal value $0.01 per share. Not for trading, but only
in connection with the listing of American Depositary Shares.
|
Item 2.02
|
Results of Operations and Financial Condition.
|
On November 12, 2019, Avadel Pharmaceuticals plc (the “Company”)
issued a press release announcing its earnings for the quarter ended September 30, 2019. That press release is attached as Exhibit
99.1 and is incorporated herein by reference.
The information responsive to this Item 2.02 of this Form 8-K,
including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934
(the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933 (the “Securities Act”) or the Exchange Act, except as may
be expressly set forth by specific reference in such a filing.
Item 9.01
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
AVADEL PHARMACEUTICALS PLC
|
|
|
|
By:
|
/s/ Phillandas T. Thompson
|
|
|
|
Phillandas T. Thompson
|
|
|
Senior Vice President, General Counsel and Corporate Secretary
|
Date: November 12, 2019
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024